SG11202100880VA - Use of riluzole oral disintigrating tablets for treating diseases - Google Patents
Use of riluzole oral disintigrating tablets for treating diseasesInfo
- Publication number
- SG11202100880VA SG11202100880VA SG11202100880VA SG11202100880VA SG11202100880VA SG 11202100880V A SG11202100880V A SG 11202100880VA SG 11202100880V A SG11202100880V A SG 11202100880VA SG 11202100880V A SG11202100880V A SG 11202100880VA SG 11202100880V A SG11202100880V A SG 11202100880VA
- Authority
- SG
- Singapore
- Prior art keywords
- disintigrating
- riluzole
- tablets
- oral
- treating diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862764864P | 2018-08-16 | 2018-08-16 | |
PCT/US2019/046709 WO2020037152A1 (en) | 2018-08-16 | 2019-08-15 | Use of riluzole oral disintigrating tablets for treating diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100880VA true SG11202100880VA (en) | 2021-02-25 |
Family
ID=69525906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100880VA SG11202100880VA (en) | 2018-08-16 | 2019-08-15 | Use of riluzole oral disintigrating tablets for treating diseases |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210315865A1 (en) |
EP (1) | EP3836922A4 (en) |
JP (2) | JP2021534160A (en) |
KR (1) | KR20210045423A (en) |
CN (1) | CN112584831A (en) |
AU (1) | AU2019322889A1 (en) |
BR (1) | BR112021002692A2 (en) |
CA (1) | CA3109769A1 (en) |
EA (1) | EA202190544A1 (en) |
IL (1) | IL280657A (en) |
MX (1) | MX2021001563A (en) |
PH (1) | PH12021550218A1 (en) |
SG (1) | SG11202100880VA (en) |
WO (1) | WO2020037152A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4171554A1 (en) * | 2020-06-24 | 2023-05-03 | Biohaven Therapeutics Ltd. | Compositions and methods for treating obsessive-compulsive disorder |
CA3193824A1 (en) * | 2020-10-05 | 2022-04-14 | Ana PEREIRA | Riluzole for the treatment of alzheimer's disease |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
CN114177153B (en) * | 2021-12-20 | 2023-04-07 | 平顶山市第二人民医院 | Riluzole orally disintegrating tablet and preparation method thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
AU2003280324A1 (en) * | 2002-11-26 | 2004-06-18 | Alk-Abello A/S | Pharmaceutical allergen product |
US9241902B2 (en) * | 2003-12-17 | 2016-01-26 | R.P. Scherer Technologies, Llc | Chewable soft capsules containing ungelatinized starch |
EP2982372B1 (en) * | 2005-04-05 | 2020-08-05 | Yale University | Glutamate modulating agents in the treatment of mental disorders |
US20080260823A1 (en) * | 2007-04-20 | 2008-10-23 | Sciele Pharma, Inc. | Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea |
AU2010282948C1 (en) * | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
US9041556B2 (en) | 2011-10-20 | 2015-05-26 | Apple Inc. | Method for locating a vehicle |
US9434704B2 (en) * | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
CN107735077A (en) * | 2014-11-21 | 2018-02-23 | 拜尔哈文制药股份有限公司 | The sublingual administration of Riluzole |
EA038518B1 (en) * | 2014-11-21 | 2021-09-09 | Биохэйвен Фармасьютикал Холдинг Компани Лтд. | Sublingual formulation of riluzole |
JP6827924B2 (en) * | 2014-11-26 | 2021-02-10 | メディシノバ・インコーポレイテッドMediciNova, Inc. | Pharmaceuticals and compositions comprising a combination of ibudilast and riluzole |
MX2017011196A (en) * | 2015-03-03 | 2018-05-22 | Biohaven Pharm Holding Co Ltd | Riluzole prodrugs and their use. |
BR112019015286A2 (en) * | 2017-01-31 | 2020-03-03 | L. Manfredi Paolo | COMPOUNDS FOR TREATING OR PREVENTING NERVOUS SYSTEM DISORDERS AND THEIR SYMPTOMS AND MANIFESTATIONS AND FOR CYTOPROTECTION AGAINST DISEASES AND AGING CELLS AND THEIR SYMPTOMS AND MANIFESTATIONS |
-
2019
- 2019-08-15 AU AU2019322889A patent/AU2019322889A1/en active Pending
- 2019-08-15 SG SG11202100880VA patent/SG11202100880VA/en unknown
- 2019-08-15 US US17/268,072 patent/US20210315865A1/en active Pending
- 2019-08-15 CA CA3109769A patent/CA3109769A1/en active Pending
- 2019-08-15 JP JP2021507740A patent/JP2021534160A/en active Pending
- 2019-08-15 EP EP19849456.9A patent/EP3836922A4/en active Pending
- 2019-08-15 WO PCT/US2019/046709 patent/WO2020037152A1/en active Application Filing
- 2019-08-15 EA EA202190544A patent/EA202190544A1/en unknown
- 2019-08-15 KR KR1020217007246A patent/KR20210045423A/en active Search and Examination
- 2019-08-15 CN CN201980054201.0A patent/CN112584831A/en active Pending
- 2019-08-15 MX MX2021001563A patent/MX2021001563A/en unknown
- 2019-08-15 BR BR112021002692-4A patent/BR112021002692A2/en unknown
-
2021
- 2021-01-28 PH PH12021550218A patent/PH12021550218A1/en unknown
- 2021-02-04 IL IL280657A patent/IL280657A/en unknown
-
2023
- 2023-10-19 JP JP2023179961A patent/JP2024010017A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210045423A (en) | 2021-04-26 |
CA3109769A1 (en) | 2020-02-20 |
EP3836922A4 (en) | 2022-05-04 |
IL280657A (en) | 2021-03-25 |
EP3836922A1 (en) | 2021-06-23 |
BR112021002692A2 (en) | 2021-05-11 |
MX2021001563A (en) | 2021-06-15 |
US20210315865A1 (en) | 2021-10-14 |
AU2019322889A1 (en) | 2021-03-04 |
PH12021550218A1 (en) | 2021-12-06 |
JP2024010017A (en) | 2024-01-23 |
JP2021534160A (en) | 2021-12-09 |
CN112584831A (en) | 2021-03-30 |
EA202190544A1 (en) | 2021-06-18 |
WO2020037152A1 (en) | 2020-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
IL288523A (en) | Compounds for treatment of pd-l1 diseases | |
SG11202011187QA (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
IL280657A (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
IL279260A (en) | Kdm1a inhibitors for the treatment of disease | |
IL264048A (en) | Pde9 inhibitors for treatment of peripheral diseases | |
IL276383B1 (en) | Treatment of ophthalmologic diseases | |
IL275321A (en) | Compounds for treatment of diseases related to dux4 expression | |
SG11202006374VA (en) | Treatment of demyelinating diseases | |
IL279397A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
IL278041A (en) | Buffered formulations of bevacizumab for use of treating diseases | |
IL291642A (en) | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases | |
IL291735A (en) | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases | |
IL282643A (en) | Combination therapy for treatment of hematological diseases | |
EP3877382A4 (en) | Novel compounds for the treatment of respiratory diseases | |
GB202015959D0 (en) | Treatment of diseases involving NAD | |
EP3619204A4 (en) | Compounds for the treatment of respiratory diseases | |
GB201805100D0 (en) | Treatment of sarcopenic diseases | |
SG11202007082PA (en) | Composition used for therapeutic treatment of skin disease | |
EP3852872C0 (en) | Composition for the treatment of the oral cavity | |
KR102090101B9 (en) | Oral composition for preventation or treatment of oral disease | |
GB201909438D0 (en) | Treatment of diseases | |
GB201912449D0 (en) | Compounds for treatment of neovascular diseases | |
GB201817344D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |